Skip to main
HSCS
HSCS logo

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is adjusting its FY26 EPS estimates upwards, reflecting an improved outlook with a projected loss of $(4.17) compared to the previous estimate of $(8.63), indicating a positive trajectory in financial performance despite ongoing losses. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm by the first half of 2026, positions the company to capitalize on a substantial market opportunity. These developments suggest a strategic enhancement of HeartSciences's offerings, making it well-poised to become a significant player in the cardiac screening technology space.

Bears say

HeartSciences Inc is currently facing significant risks that could negatively impact its stock performance, including balance sheet and liquidity challenges, as well as the potential failure of its product candidates to demonstrate necessary safety and efficacy in clinical trials. Furthermore, the company has revised its FY2026 revenue estimate downward from $1.2 million to $0.1 million, primarily due to delays in obtaining FDA approvals, signaling potential difficulties in product commercialization and reimbursement processes. Additionally, external factors such as competition, macroeconomic conditions, and fluctuating investor sentiment towards healthcare stocks further complicate the company’s growth prospects and contribute to a negative outlook for its stock.

HSCS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 2 analysts, HSCS has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.